Health Trials

Investigation of the Influence of the Human Microbiome on Giant Cell Arteritis

ConditionGiant Cell Arteritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Bonn

About this trial

The longitudinal observational study aims to assess the impact of the microbiome especially the gut-microbiome in the emergence and course of giant cell arteritis (abbr. GCA) patients. At diagnosis and 6 month follow up we will analyze the oral, blood and gut microbiome from GCA patients and healthy controls. Thereby identified potential candidate biota will be further analyzed for possible interactions and influence on the immune system.

Eligibility criteria

Qualifiers

None

Disqualifiers

chronic infection (viral, fungi, bacteria) including human immunodeficiency viruses, Hepatitis B/C

acute infection with usage of antibiotics less then 90 days before screening

major gastro-intestinal surgery <5 years from screening

gastro-intestinal bleeding <90 days before screening

Trial design

Treatments tested in this trial

  • Analysis of blood and microbiome samples (stool, oral lavage)

Treatment groups

50 Participants
are divided into 2 treatment groups

Locations

2
Clinic of Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn53127, BonnNorth Rhine-Westphalia, Germany
University Hospital Bonn53127, Bonn Germany

Sponsors and collaborators

University of Bonn

Lead sponsor

Source ClinicalTrials.gov